论文部分内容阅读
具有纤维蛋白特异性的两种纤溶酶原激活剂,即组织型纤容酶原激活剂(t-PA)和单链尿激酶型纤溶酶原激活剂(Scu-PA),临床研究证明是特异性血栓溶解剂.需要获得快速的冠脉再灌注,通常是以1～3小时输入40～80毫克的速度进行输注,但在一些病人身上发现有激活全身性纤维蛋白溶解和纤维蛋白原分解的作用.动物试验观察到t-PA和scu-PA之间、t-AA和尿激酶之间,有活泼迅速的协同作用.本文作者们选用急性心肌梗塞(AMI)和冠脉动脉闭塞患者进行联合用药中协同作用的研究。
Two fibrinogen-specific plasminogen activators, namely tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (Scu-PA), have been clinically proven Is a specific thrombolytic agent and requires rapid coronary reperfusion, which is usually infused at a rate of 40-80 mg for 1 to 3 hours, but systemic fibrinolysis and fibrin activation are found in some patients The role of the original decomposition of animal experiments observed t-PA and scu-PA, t-AA and urokinase between the lively and rapid synergy. The authors selected acute myocardial infarction (AMI) and coronary artery occlusion Study of synergistic effect in patients with combination therapy.